March 7, 2022
Eisai has started the submission of application data for its Alzheimer’s drug lecanemab under the Pharmaceuticals and Medical Devices Agency’s (PMDA) prior assessment consultation system in a bid to gain its early approval in Japan, the company and US partner...read more